Literature DB >> 19626426

Arsonoliposomes for the potential treatment of medulloblastoma.

Marco E Favretto1, Showan Marouf, Panagiotis Ioannou, Sophia G Antimisiaris, Terence L Parker, Paraskevi Kallinteri.   

Abstract

PURPOSE: To investigate the arsonoliposome effect on medulloblastoma cells (VC312Rs) related to uptake, endocytotic mechanism and cell viability.
METHODS: VC312R viability in presence of either arsonoliposomes or stealth liposomes was studied using MTT assay for 1-4 days. Fibroblasts (3T3) were used as control. Apoptosis was studied for 2 h, 5 h and 24 h. Bodipy-labelled arsonoliposome uptake (time- and dose-dependent) was estimated using FACS analysis. The endocytotic mechanism was investigated using inhibitors of clathrin- (chlorpromazine) and caveolae-mediated endocytosis (filipin).
RESULTS: Arsonoliposomes affected significantly the VC312R viability compared to 3T3 cells and induced apoptosis to VC312Rs after 2 h of incubation. Apoptosis was not observed for 3T3 cells. Liposome uptake versus time showed a bimodal pattern. Clathrin-mediated endocytosis was the main endocytotic mechanism at low lipid concentrations and caveolae at higher ones; thus, dose-dependent uptake did not show a plateau at increased lipid concentrations.
CONCLUSIONS: Arsonoliposomes showed "selective" toxicity towards medulloblastoma cells inducing apoptosis after 2 hs of incubation. Therefore, arsonoliposomes are promising anticancer vehicles for brain tumour treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19626426     DOI: 10.1007/s11095-009-9940-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

Review 1.  Caveolae: an alternative membrane transport compartment.

Authors:  M Gumbleton; A G Abulrob; L Campbell
Journal:  Pharm Res       Date:  2000-09       Impact factor: 4.200

2.  Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis.

Authors:  Joanna Rejman; Volker Oberle; Inge S Zuhorn; Dick Hoekstra
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

3.  Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.

Authors:  J Dai; R S Weinberg; S Waxman; Y Jing
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

4.  Arsonoliposome interaction with thiols: effect of pegylation and arsonolipid content of arsonoliposomes on their integrity during incubation in glutathione.

Authors:  Maria N Haikou; Paraskevi Zagana; Panayiotis V Ioannou; Sophia G Antimisiaris
Journal:  J Nanosci Nanotechnol       Date:  2006 Sep-Oct

5.  High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors.

Authors:  M A Castello; A Clerico; G Deb; C Dominici; P Fidani; A Donfrancesco
Journal:  Am J Pediatr Hematol Oncol       Date:  1990

Review 6.  Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure.

Authors:  M van Engeland; L J Nieland; F C Ramaekers; B Schutte; C P Reutelingsperger
Journal:  Cytometry       Date:  1998-01-01

7.  Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers.

Authors:  H A Andree; C P Reutelingsperger; R Hauptmann; H C Hemker; W T Hermens; G M Willems
Journal:  J Biol Chem       Date:  1990-03-25       Impact factor: 5.157

8.  Treatment of malignant scala posterior brain tumors in children: the chemotherapy of relapsed medulloblastoma with a dibromdulcitol containing drug regime and pharmacokinetic studies of dibromdulcitol in children.

Authors:  D Schuler; P Somló; R Koóos; R Kálmánchey; E Paraicz
Journal:  Med Pediatr Oncol       Date:  1992

Review 9.  Medulloblastoma: molecular genetics and animal models.

Authors:  Corey Raffel
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

Review 10.  The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.

Authors:  Andrew M Evens; Martin S Tallman; Ronald B Gartenhaus
Journal:  Leuk Res       Date:  2004-09       Impact factor: 3.156

View more
  2 in total

1.  Permeability of PEGylated immunoarsonoliposomes through in vitro blood brain barrier-medulloblastoma co-culture models for brain tumor therapy.

Authors:  Abdulghani Al-Shehri; Marco E Favretto; Panayiotis V Ioannou; Ignacio A Romero; Pierre-Olivier Couraud; Babette Barbash Weksler; Terry L Parker; Paraskevi Kallinteri
Journal:  Pharm Res       Date:  2014-09-19       Impact factor: 4.200

2.  Synthesis of Novel Arsonolipids and Development of Novel Arsonoliposome Types.

Authors:  Spyridon Mourtas; Konstantina Papadia; Golfo G Kordopati; Panayiotis V Ioannou; Sophia G Antimisiaris; Gerasimos M Tsivgoulis
Journal:  Pharmaceutics       Date:  2022-08-08       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.